Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
| Autor: | Ronald M. Goldenberg, Alice Y.Y. Cheng, Tess Fitzpatrick, Jeremy D. Gilbert, Subodh Verma, Julia J. Hopyan |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Advanced and Specialized Nursing
Stroke endocrine system Diabetes Mellitus Type 2 Glucagon-Like Peptide 1 digestive oral and skin physiology Humans Neurology (clinical) Neurologists Cardiology and Cardiovascular Medicine hormones hormone substitutes and hormone antagonists Glucagon-Like Peptide-1 Receptor |
| Zdroj: | Stroke. 53(5) |
| ISSN: | 1524-4628 |
| Popis: | People living with diabetes are at higher risk for stroke and have a poorer prognosis following a stroke event than those without diabetes. Data from cardiovascular outcome trials and meta-analyses indicate that GLP-1RAs (glucagon-like peptide 1 receptor agonists) reduce the risk of stroke in individuals with type 2 diabetes. Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes. The current work summarizes evidence supporting the use of GLP-1RAs for stroke reduction in people with type 2 diabetes and offers 2 new resources for neurologists who are considering GLP-1RAs for their patients—a list of frequently asked questions with evidence-based answers on safely initiating and managing GLP-1RAs, and a practical decision-making algorithm to assist in using GLP-1RAs as part of a stroke reduction strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|